{
    "clinical_study": {
        "@rank": "95791", 
        "arm_group": {
            "arm_group_label": "KHK7580", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study is designed to evaluate safety, pharmacokinetics and pharmacodynamics after\n      single and multiple administration of KHK7580 for secondary hyperparathyroidism in patients\n      receiving hemodialysis"
        }, 
        "brief_title": "Phase 1/2 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Hyperparathyroidism", 
        "condition_browse": {
            "mesh_term": [
                "Hyperparathyroidism", 
                "Hyperparathyroidism, Secondary"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent\n\n          -  Stable chronic renal disease patients receiving hemodialysis 3 times weekly for at\n             least 12 weeks prior to the screening\n\n          -  intact PTH value \u2265 240 pg/mL at the screening\n\n          -  Corrected serum calcium \u2265 8.4 mg/dL at the screening\n\n        Exclusion Criteria:\n\n          -  Patients with primary hyperparathyroidism\n\n          -  Patients who received cinacalcet within 2 weeks prior to the screening\n\n          -  Patients with change in dose or dosing regimen of active vitamin D/ its analogs,\n             phosphate binders and/or calcium containing compounds within 2 weeks prior to the\n             screening\n\n          -  Patients who received parathyroidectomy and/or parathyroid intervention\n\n          -  Patients with uncontrolled hypertension and/or diabetes\n\n          -  Patients with severe heart disorder\n\n          -  Patients with severe hepatic disease\n\n          -  Patients who take investigational drug in other clinical trial within 12 weeks prior\n             to the screening\n\n          -  Patients who have been judged ineligible to participate in the study by the\n             investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "74 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01935856", 
            "org_study_id": "7580-003"
        }, 
        "intervention": {
            "arm_group_label": "KHK7580", 
            "description": "Oral administration", 
            "intervention_name": "KHK7580", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "patients", 
            "receiving", 
            "hemodialysis", 
            "Secondary"
        ], 
        "lastchanged_date": "May 16, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tokyo", 
                    "country": "Japan"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin"
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Dose Escalation, Single and Multiple Dose, Phase 1/2 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The safety of KHK7580 assessed by number and types of adverse events, laboratory tests, vital signs, electrocardiogram and ophthalmic examination", 
            "measure": "The safety of KHK7580 assessed by number and types of adverse events, laboratory tests, vital signs, electrocardiogram and ophthalmic examination", 
            "safety_issue": "Yes", 
            "time_frame": "For 19 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01935856"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Pharmacokinetic parameters such as Maximum concentration (Cmax), time to maximum concentration (tmax), area under the curve (AUC), half-life (t1/2), and etc., are assessed.", 
                "measure": "Profiles of pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, 0.5, 1,  2, 4, 8, 12, 24, 48 and 72 hours post each single dosing, and pre-dose in Day 1, 3, 5, 8, 12 and 15 in multiple dose period"
            }, 
            {
                "description": "intact PTH, whole PTH, corrected serum calcium, phosphorus, intact FGF23, ionized calcium, calcitonin", 
                "measure": "Profiles of pharmacodynamics", 
                "safety_issue": "No", 
                "time_frame": "For 4-15 days after every dosing"
            }
        ], 
        "source": "Kyowa Hakko Kirin Company, Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kyowa Hakko Kirin Company, Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}